Stocktoria
RxSight, Inc. RXST
RxSight, Inc. (RXST) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $134.5M at a -29.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.12 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.838 |
| Retained earnings / assets | -2.12 |
| EBIT / assets | -0.155 |
| Equity / liabilities | 7.63 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RXST | RxSight, Inc. | 2/9 | 5.56 | — | -3.9% |
| STAA | STAAR SURGICAL CO | 1/9 | 4.46 | — | -23.7% |
| LUCY | Innovative Eyewear Inc | 4/9 | — | — | — |
| WRBY | Warby Parker Inc. | 5/9 | -0.22 | — | +13% |
| EYE | National Vision Holdings, Inc. | 7/9 | 0.82 | 51 | +9% |
| COO | COOPER COMPANIES, INC. | 6/9 | 4.99 | 36.9 | +5.1% |
| BLCO | Bausch & Lomb Corp | 3/9 | 1.24 | — | +6.5% |
About RxSight, Inc.
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
FAQ
Is RXST financially healthy?
RxSight, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does RXST pay a dividend?
No, RxSight, Inc. does not currently pay a dividend.
How profitable is RXST?
In FY2025, RxSight, Inc. had a net margin of -29.0% and a return on equity of -14.1%.
What is the analyst price target for RXST?
The average Wall-Street price target for RxSight, Inc. is $8.79, about 24.4% above the recent price, from 7 analysts.
Is RXST a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RxSight, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.